Drug

Adagrasib

Approved · EMA

ClassGTPase KRas inhibitorEmerging researchLate-stage developmentRising momentum

Also known as KRAS G12C inhibitor MRTX849, Krazati, ((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile, 2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-.

RxNorm2625882 ChEMBLCHEMBL4594350 ATCL01XX77UNII8EOO6HQF8Y

Research papers

Active clinical trials

GTPase KRas

Primary target

Regulatory events

Latest activity

beta

Recent clinical, regulatory, research and industry developments relating to this drug.

A Randomized Study of Two Dosing Regimens of Adagrasib in Patients With Previously Treated Non-Small Cell Lung Cancer With KRAS G12C Mutation

Clinical trial2026-07-30Primary completion · ClinicalTrials.gov

A Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Advanced Non-Small Cell Lung Cancer With KRAS G12C Mutation

Clinical trial2026-07-09Results expected Q4 2028 · ClinicalTrials.gov

A Randomized, Double-Blind, Phase 3 Trial of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated, Locally Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)

Clinical trial2026-07-08Results expected Q3 2029 · ClinicalTrials.gov

A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

Clinical trial2026-07-02Results expected Q4 2027 · ClinicalTrials.gov

Solid Tumor Study for Long Term Treatment of Cancer Patients Who Have Participated in BMS Parent Studies Investigating Adagrasib (BMS-986503)

Clinical trial2026-06-30Results expected Q1 2028 · ClinicalTrials.gov

A Multicenter Phase 1b/2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations

Clinical trial2026-06-26Results expected Q1 2029 · ClinicalTrials.gov

ASCEND-CRC: Profiling and Targeting Dynamic Tumor Resistance in Patients With Metastatic Colorectal Cancer

Clinical trial2026-06-11Results expected Q4 2027 · ClinicalTrials.gov

Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.

Research2024-06-01Cancer discovery

Approval: Krazati (EMA)

Regulatory2024-01-05EMA

Adagrasib in Advanced Solid Tumors Harboring a KRASG12C Mutation.

Research2023-04-26Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Adagrasib with or without Cetuximab in Colorectal Cancer with Mutated KRAS G12C.

Research2022-12-21The New England journal of medicine

Adagrasib in Non-Small-Cell Lung Cancer Harboring a KRASG12C Mutation.

Research2022-06-03The New England journal of medicine

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name

Adagrasib

Aliases & brands

KRAS G12C inhibitor MRTX849Krazati((2s)-4-(7-(8-chloronaphthalen-1-yl)-2-(((2s)-1- methylpyrrolidin-2-yl)methoxy)-5,6,7,8- tetrahydropyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoroprop2-enoyl)piperazin-2-yl)acetonitrile2-piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2s)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2s)-

RxNorm CUI

2625882

ChEMBL ID

CHEMBL4594350

ATC codes

L01XX77

UNII

8EOO6HQF8Y

Primary mechanism

GTPase KRas inhibitor

Regulatory jurisdictions

ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

GTPase KRas

KRAS · P01116

INHIBITORGTPase KRas inhibitor

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval

2024-01-05

Latest approval

2024-01-05

Authorities

EMA

Total events

emaEuropean Medicines Agency· 1 event

2024-01-05Approval

Approval: Krazati (EMA)

Indication: Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at… Show full indication

Krazati as monotherapy is indicated for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with KRAS G12C mutation and disease progression after at least one prior systemic therapy.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.